Immatics US, Inc.
Clinical trials sponsored by Immatics US, Inc., explained in plain language.
A biotechnology company developing T-cell receptor-based immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Personalized cell therapy takes on advanced melanoma in major trial
Disease control Recruiting nowThis Phase 3 trial tests a one-time cell therapy called IMA203 for people with advanced melanoma that has not responded to prior treatment. IMA203 is made from a patient's own immune cells and is designed to target cancer cells. The study compares IMA203 to standard treatments li…
Phase 3 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Engineered T-Cells take on recurrent solid tumors in new trial
Disease control Recruiting nowThis study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…
Phase 1/2 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cell therapy combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has not responded to prior treatments. The main goals are to check safety and find the best dose. About 15 participa…
Phase 1 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC